Novartis Buys Avidity: A $12 Billion Bet on Muscle Disorders
Update: 2025-10-27
Description
Novartis is set to acquire Avidity Biosciences for $12 billion, gaining access to Avidity's promising rare muscle disorder treatments. The deal, expected to close by 2026, involves Novartis paying $72 per share, a 46% premium, while Avidity spins off its cardiology programs into a new company. This move continues Novartis's acquisition spree, aimed at bolstering its pipeline in the face of fierce competition.
The Daily News Now! — Every city. Every story. AI-powered.
Hosted on Acast. See acast.com/privacy for more information.
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
x
